Author:
Dalens Lorraine,Niogret Julie,Richard Corentin,Chevrier Sandy,Foucher Pascal,Coudert Bruno,Lagrange Aurélie,Favier Laure,Westeel Virginie,Kim Stefano,Adotevi Olivier,Chapusot Caroline,Martin Laurent,Arnould Laurent,Kaderbhai Courèche-Guillaume,Boidot Romain
Abstract
Abstract
Background
Non-small cell lung cancer is a very poor prognosis disease. Molecular analyses have highlighted several genetic alterations which may be targeted by specific therapies. In clinical practice, progression-free survival on EGFR TKI treatment is between 12 and 14 months. However, some patients progress rapidly in less than 6 months, while others remain free of progression for 16 months or even longer during EGFR TKI treatment.
Methods
We sequenced tumor exomes from 135 lung cancer patients (79 with EGFR-wildtype (WT), 56 with EGFR-mutant tumors) enrolled in the ALCAPONE trial (genomic analysis of lung cancers by next generation sequencing for personalized treatment).
Results
Some germline polymorphisms were enriched in the EGFR-mutant subset compared to EGFR-WT tumors or to a reference population. However, the most interesting observation was the negative impact of some germline SNPs in immunity-related genes on survival on EGFR TKI treatment. Indeed, the presence of one of three particular SNPs in the HLA-DRB5 gene was associated with a decreased PFS on EGFR TKI. Moreover, some SNPs in the KIR3DL1 and KIR3DL2 genes were linked to a decrease in both progression-free and overall survival of patients with EGFR-mutant tumors.
Conclusion
Our data suggest that SNPs in genes expressed by immune cells may influence the response to targeted treatments, such as EGFR TKIs. This indicates that the impact of these cells may not be limited to modulating the response to immunotherapies. Further studies are needed to determine the exact mechanisms underlying this influence and to identify the associated predictive and prognostic markers that would allow to refine treatments and so improve lung cancer patient outcomes.
Trial registration
NCT02281214: NGS Genome Analysis in Personalization of Lung Cancer Treatment (ALCAPONE).
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Molecular Medicine
Reference15 articles.
1. Bramswig NC, Zaki MS. UNC80 Deficiency. 2017 Sep 21 [updated 2023 May 18]. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle: University of Washington, Seattle; 1993–2023. PMID: 28933810.
2. Wang H, Ren D. UNC80 functions as a scaffold for Src kinases in NALCN channel function. Channels (Austin). 2009;3:161–3.
3. Perez-Morales R, Gonzalez-Zamora A, Gonzalez-Delgado MF, Calleros Rincon EY, Olivas Calderon EH, Martinez-Ramirez OC, Rubio J. CHRNA3 rs1051730 and CHRNA5 rs16969968 polymorphisms are associated with heavy smoking, lung cancer, and chronic obstructive pulmonary disease in a Mexican population. Ann Hum Genet. 2018;82:415–24.
4. Qu X, Wang K, Dong W, Shen H, Wang Y, Liu Q, Du J. Association between two CHRNA3 variants and susceptibility of lung cancer: a meta-analysis. Sci Rep. 2016;6:20149.
5. Guo Z, Zhang T, Wu J, Wang H, Liu X, Tian L. Genetic polymorphisms in COL18A1 influence the development of osteosarcoma. Int J Clin Exp Pathol. 2015;8:11531–6.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献